Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Cardoso, PN (Author) Other; Pinheiro, AF (Author) Other; Meira, J (Author) Other; Pedrosa, AC (Author) Other; Manuel Falcão (Author) FMUP; Pinheiro Costa, J (Author) Other; Falcão-Reis F (Author) FMUP; Ângela Carneiro (Author) FMUP

Journal

Title: Journal of Ophthalmology

Vol. 2017

Pages: 1-6

ISSN: 2090-004X

Publisher: Hindawi

Indexing

ISI Web of Knowledge - 8 Citations

Scopus - 9 Citations

Other information

Authenticus ID: P-00N-6KZ

DOI: 10.1155/2017/6835782

Abstract (EN): Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p < 0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6